Idenix Pharmaceuticals (IDIX) Tops Q3 EPS by 20c
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals (NASDAQ: IDIX) reported Q3 EPS of $0.03, $0.20 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $32.3 million, versus $2.6 million reported last year.
2012 Financial Guidance
At September 30, 2012, Idenix's cash and cash equivalents totaled $251.9 million. The Company expects that its current cash and cash equivalents will be sufficient to sustain its operations through at least March 31, 2014. This guidance assumes no milestone payments, license fees, reimbursement for development programs and no financing activities.
For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.
2012 Financial Guidance
At September 30, 2012, Idenix's cash and cash equivalents totaled $251.9 million. The Company expects that its current cash and cash equivalents will be sufficient to sustain its operations through at least March 31, 2014. This guidance assumes no milestone payments, license fees, reimbursement for development programs and no financing activities.
For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Kimberly Clark (KMB) PT Raised to $150 at HSBC
- QNB Corp. (QNBC) Reports Q1 EPS of $0.71
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
